Zafgen

ZFGN NASDAQ
1.160
+0.010
+0.87%
已收盘, 16:00 07/18 EDT
开盘
1.150
昨收
1.150
最高
1.180
最低
1.130
成交量
13.72万
成交均量(3M)
32.13万
52周最高
12.36
52周最低
1.140
换手率
0.37%
市值
4,329.92万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Zafgen ZFGN股票价格,Zafgen股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company uses its proprietary methionine aminopeptidase 2 (MetAP2) biology platform to develop novel therapies for patients affected by complex metabolic diseases. Its product candidate is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor that is used to treat type 2 diabetes and other related metabolic disorders. Type 2 diabetes is a prevalent, chronic, progressive and multifactorial disorder that leads to increased microvascular and macrovascular disease and as such increases risk of death from cardiovascular disease, stroke, and kidney failure. Its MetAP2 development candidate ZGN-1258 is administered by subcutaneous injection. ZGN-1258 is used for the treatment of Prader-Willi syndrome (PWS). PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms including hyperphagia, uncontrollable hunger and its related behaviors, and obesity.
展开 >

最近浏览

名称
价格
涨跌幅